BACKGROUND: Recent progress in the cardiotypic differentiation of embryonic and somatic stem cells opens novel prospects for the treatment of cardiovascular disorders. The aim of the present study was to develop a novel surgical approach that allows standardized cellular cardiomyoplasty in mouse with low-perioperative mortality. METHODS: Reproducible transmural lesions were generated by cryoinjury followed by intramural injection of embryonic cardiomyocytes using a newly designed holding device and vital dye staining. This approach was validated with a transgenic mouse model, in which the live reporter gene-enhanced green fluorescent protein (EGFP) is under control of a cardiac-specific promoter. RESULTS: The perioperative mortality was 10%. The engrafted EGFP-positive cardiomyocytes could be identified in a high percentage (72.2%, n=36) of operated animals. CONCLUSIONS: This novel approach enables reliable cellular replacement therapy in mouse and greatly facilitates the analysis of its molecular, cellular, and functional efficacy.
BACKGROUND: Recent progress in the cardiotypic differentiation of embryonic and somatic stem cells opens novel prospects for the treatment of cardiovascular disorders. The aim of the present study was to develop a novel surgical approach that allows standardized cellular cardiomyoplasty in mouse with low-perioperative mortality. METHODS: Reproducible transmural lesions were generated by cryoinjury followed by intramural injection of embryonic cardiomyocytes using a newly designed holding device and vital dye staining. This approach was validated with a transgenic mouse model, in which the live reporter gene-enhanced green fluorescent protein (EGFP) is under control of a cardiac-specific promoter. RESULTS: The perioperative mortality was 10%. The engrafted EGFP-positive cardiomyocytes could be identified in a high percentage (72.2%, n=36) of operated animals. CONCLUSIONS: This novel approach enables reliable cellular replacement therapy in mouse and greatly facilitates the analysis of its molecular, cellular, and functional efficacy.
Authors: Michael Hesse; Alexandra Raulf; Gregor-Alexander Pilz; Christian Haberlandt; Alexandra M Klein; Ronald Jabs; Holm Zaehres; Christopher J Fügemann; Katrin Zimmermann; Jonel Trebicka; Armin Welz; Alexander Pfeifer; Wilhelm Röll; Michael I Kotlikoff; Christian Steinhäuser; Magdalena Götz; Hans R Schöler; Bernd K Fleischmann Journal: Nat Commun Date: 2012 Impact factor: 14.919
Authors: Eugen Kolossov; Toktam Bostani; Wilhelm Roell; Martin Breitbach; Frank Pillekamp; Jens M Nygren; Philipp Sasse; Olga Rubenchik; Jochen W U Fries; Daniela Wenzel; Caroline Geisen; Ying Xia; Zhongju Lu; Yaqi Duan; Ralf Kettenhofen; Stefan Jovinge; Wilhelm Bloch; Heribert Bohlen; Armin Welz; Juergen Hescheler; Sten Eirik Jacobsen; Bernd K Fleischmann Journal: J Exp Med Date: 2006-09-05 Impact factor: 14.307
Authors: Alexandra Raulf; Hannes Horder; Laura Tarnawski; Caroline Geisen; Annika Ottersbach; Wilhelm Röll; Stefan Jovinge; Bernd K Fleischmann; Michael Hesse Journal: Basic Res Cardiol Date: 2015-04-30 Impact factor: 17.165
Authors: Merry L Lindsey; Roberto Bolli; John M Canty; Xiao-Jun Du; Nikolaos G Frangogiannis; Stefan Frantz; Robert G Gourdie; Jeffrey W Holmes; Steven P Jones; Robert A Kloner; David J Lefer; Ronglih Liao; Elizabeth Murphy; Peipei Ping; Karin Przyklenk; Fabio A Recchia; Lisa Schwartz Longacre; Crystal M Ripplinger; Jennifer E Van Eyk; Gerd Heusch Journal: Am J Physiol Heart Circ Physiol Date: 2018-01-12 Impact factor: 4.733
Authors: Leonie E Paulis; Alexandra M Klein; Alexander Ghanem; Tessa Geelen; Bram F Coolen; Martin Breitbach; Katrin Zimmermann; Klaas Nicolay; Bernd K Fleischmann; Wilhelm Roell; Gustav J Strijkers Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240